Nicardipine
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
- Nicardipine
- Nicardipine: From Hypertension to Pulmonary Hypertension with Unclear Multifactorial Mechanism
Nicardipine: From Hypertension to Pulmonary Hypertension with Unclear Multifactorial Mechanism
One-Sentence Summary
Nicardipine is a dihydropyridine calcium channel blocker; no formal original-indication or mechanism-of-action data is recorded in this evidence pack, though it is widely known for use in hypertensive emergencies. The TxGNN model’s top-ranked prediction is Pulmonary Hypertension with Unclear Multifactorial Mechanism, but this is supported by 0 clinical trials and 0 publications, and the model’s own mechanistic rationale flags safety concerns rather than therapeutic support.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in evidence pack (drug class: dihydropyridine calcium channel blocker) |
| Predicted New Indication | Pulmonary hypertension with unclear multifactorial mechanism |
| TxGNN Prediction Score | 99.26% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for Nicardipine in this evidence pack (flagged as a High-severity data gap, DG002). Based on the mechanistic notes accompanying the predictions, Nicardipine is understood to be a dihydropyridine calcium channel blocker whose core pharmacology is systemic vasodilation and blood pressure reduction; the intravenous formulation is widely used in clinical practice for hypertensive emergencies.
For the top-ranked prediction — pulmonary hypertension with unclear multifactorial mechanism — the model’s own rationale is not supportive: calcium channel blockers are only effective in a small, vasoreactivity-positive subset of Group 1 idiopathic pulmonary arterial hypertension, identified only after formal acute vasodilator testing, and this indication label is too ambiguous to confirm that subgroup. The rank 2 candidate (pulmonary hypertension due to lung disease/hypoxia, WHO Group 3) is explicitly flagged in the evidence as potentially harmful — non-selective vasodilators can blunt hypoxic pulmonary vasoconstriction, worsening V/Q mismatch and hypoxaemia — and the rationale recommends this association be excluded rather than pursued.
The more mechanistically coherent candidates in this dataset are ranked 3 and 4 (malignant renovascular hypertension; malignant hypertensive renal disease), where Nicardipine’s established IV use in hypertensive emergency provides a plausible pharmacological link. However, these remain at evidence level L4 with zero supporting trials or literature in this pack, and rank 5 (Braddock syndrome) is most likely knowledge-graph noise with no known pathophysiological connection to calcium channel blockade.
Clinical Trial Evidence
Currently no related clinical trials registered.
(This applies to all five predicted indications in this evidence pack, including malignant renovascular hypertension and malignant hypertensive renal disease.)
Literature Evidence
Currently no related literature available.
(No publications are recorded for any of the five predicted indications.)
UK Market Information
Nicardipine is not marketed in the UK per this evidence pack, and no marketing authorisations are currently on file (0 licenses recorded). No dosage form or approved-indication data is available for reference.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: MHRA-equivalent labelled warnings and contraindications for Nicardipine are recorded as a Blocking data gap (DG001) in this evidence pack — this means an initial safety screen (S1) cannot currently be completed, and no safety table can be populated from source data.
Conclusion and Next Steps
Decision: Hold
Rationale: All five predicted indications rest on TxGNN model scores alone, with zero supporting clinical trials or literature (evidence level L4–L5). The two highest-scoring predictions are mechanistically weak or actively flagged as potentially harmful rather than therapeutic. The drug also has no current UK marketing authorisation, and a Blocking-severity gap in labelled safety data (warnings/contraindications) prevents any meaningful safety evaluation at this stage.
To proceed, the following is needed:
- MHRA/SmPC-equivalent warnings and contraindications (resolve DG001, Blocking)
- Confirmed mechanism of action from DrugBank or equivalent source (resolve DG002)
- Independent literature/trial search specifically for malignant renovascular hypertension and malignant hypertensive renal disease (the more mechanistically plausible candidates), since none are currently captured in this pack
- Re-evaluation of the pulmonary hypertension candidates against current WHO Group 1/Group 3 clinical guidance before any further consideration
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.